MUMBAI, India, Aug. 24 -- Intellectual Property India has published a patent application (202641098372 A) filed by Chaitanya Deemed To Be University on August 13, 2026, for A Novel Benzothiazole–thiazolidine-2,4-Dione–1,2,3-Triazole Hybrid Compound, Pharmaceutical Composition Thereof, And Method For The Preparation And Therapeutic Application Thereof.
Inventors include Dr. M. Ravinder; Advaitha Vanaparthy; and Dr. T. Narasimha Swamy.
The application for the patent was published on August 21, 2026, under issue no. 34/2026.
Abstract: The present invention relates to novel benzothiazole–thiazolidine-2,4-dione–1,2,3-triazole hybrid compounds, pharmaceutical compositions thereof, and a method for their preparation for therapeutic applications. The disclosed compounds integrate benzothiazole, thiazolidine-2,4-dione, and 1,2,3-triazole pharmacophores into a single molecular framework to enhance biological activity against vascular endothelial growth factor receptor-2 (VEGFR-2). The compounds are synthesized through sequential Knoevenagel condensation, azidation, and copper(I)-catalyzed azide–alkyne cycloaddition reactions, followed by purification and structural characterization using spectroscopic and analytical techniques. The synthesized compounds are evaluated through molecular docking, VEGFR-2 enzyme inhibition, and in vitro antiproliferative studies against human cancer cell lines to identify lead candidates with improved receptor affinity and anticancer potential. The invention further provides pharmaceutical compositions comprising the disclosed compounds for inhibiting VEGFR-2-mediated angiogenesis and abnormal cellular proliferation, thereby providing promising lead molecules for targeted anticancer drug discovery and therapeutic development.
Disclaimer: Curated by HT Syndication.
